David Sinclair has announced 'v2,' a chemical compound for whole-body rejuvenation that he describes as fundamentally different from the 'v1' gene therapy already in human trials, and has begun publicly presenting data on it at a Harvard conference

David Sinclair has announced 'v2,' a chemical compound for whole-body rejuvenation that he describes as fundamentally different from the 'v1' gene therapy already in human trials, and has begun publicly presenting data on it at a Harvard conference

On September 30, David Sinclair, a professor at Harvard Medical School, wrote on X that his lab is ready to publicly present its 'v2' technology, which is fundamentally different from 'v1' (ER-100), the gene therapy currently being injected into a single eye of patients with glaucoma and other ocular conditions in a human clinical trial. The lab is disclosing v2 data in two installments at the ARDD 2026 conference at Harvard: a talk by lab graduate student Chris Petty on Thursday has already taken place, and Sinclair's own presentation is scheduled for Saturday.

ER-100 is a gene therapy: a viral vector delivers three genes into the cell, the Yamanaka factors OCT4, SOX2, and KLF4, which temporarily activate a program that erases age-related damage while preserving cell identity. The method works but is physically limited: the viral vector cannot reliably reach all organs through the bloodstream, so the gene must be injected directly into the target organ. For ER-100, that organ is a single eye. 'v2' works differently: it is a molecule that circulates through the body in the bloodstream and can in principle reach any tissue, and treatment can be stopped, unlike a one-time genetic intervention.

As early as 2023, Sinclair's lab published a screen of eighty chemical mixtures and identified several that reduced biological age in cell culture as effectively as the three genes themselves, while preserving cell identity. Translating this into a living organism proved harder. The neighboring lab of Vadim Gladyshev (who is also on the ARDD organizing committee) tested a similar seven-compound mixture in mice using subcutaneously implanted pumps. The result, in Gladyshev's own words: 'At low concentrations there was no effect, and high concentrations were toxic.' The animals' livers and kidneys filled with lipid droplets, and the mice rapidly lost weight.

Sinclair claims that his candidate, code-named SL-100 (an improved version of his earlier six-factor cocktail), has been undergoing closed animal testing for over a year and has already shown effects in the brain, kidneys, muscles, and motor neurons. He calls the composition 'extremely, extremely confidential': safety and efficacy must be fully verified first. Sergey Velichko, founder of a competing cell-reprogramming company, cautions that such compounds are used at very high concentrations in laboratory practice, precisely the risk zone where Gladyshev's experiments produced toxicity.

Petty's Thursday talk was titled 'Chemical Epigenetic Reprogramming Reduces Signs of Aging in Cell Culture and In Vivo.' The title claims success exactly where the neighboring lab did not succeed. The talk was delivered at the ARDD conference, which half a year ago moved from Copenhagen to Boston and reoriented itself toward pharma, which is why this year's audience includes senior executives from Novartis, Pfizer, Moderna, Takeda, and representatives of the FDA. The lab has not published data on doses or safety. Sinclair's Saturday presentation will show whether his own data meet the standard of evidence claimed in the title of Petty's talk.